Clinical Validation of a Point-of-Care Whole Blood Coagulometer in Patients on Factor Xa Inhibitors
ClotChek clotting times showed good sensitivity and specificity to identify meaningful anticoagulation among patients taking apixaban or rivaroxaban, and could aid physicians at the point of care in making therapeutic decisions in patients with adverse events associated with oral factor Xa inhibitors.